Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease

Benzer Materyaller

• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  Yazar:: Walters, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
  Yazar:: Keshav, S, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  Yazar:: Bekker, P, ve diğerleri
  Baskı/Yayın Bilgisi: (2007)
• CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
  Yazar:: Wendt, E, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
  Yazar:: Wendt E, ve diğerleri
  Baskı/Yayın Bilgisi: (2015-04-01)